Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease
Acta Neuropathologica · 19.05.2025 · 149 (1)
DOI: 10.1007/s00401-025-02889-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 19.05.2025. Verfasst von Clíona Farrell und 15 weiteren Autor:innen. Beteiligte Einrichtung: UK Dementia Research Institute at University College London, London, UK. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, Apolipoproteins E, Brain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rosetrees Trust, NIA NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome–Alzheimer’s disease (DSAD) to demographically matched cases of early onset AD and healthy ageing controls. We find dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells, and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high risk of early onset dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UK Dementia Research Institute at University College London, London, UK.
- Queen Square Institute of Neurology, University College London, London, UK.
- UCL Great Ormond Street Institute of Child Heath, University College London, London, UK.
- Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.
- Mathematical, Computational, and Systems Biology (MCSB) Program, University of California, Irvine, Irvine, CA, USA.
- Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, Irvine, CA, USA.
Förderung
- Rosetrees Trust
- NIA NIH HHS
- Alzheimer's Association
- Alzheimer's Society
- Alzheimer's Research UK
- Fondation Jérôme Lejeune
- UK Dementia Research Institute
- NCATS NIH HHS
Zitieren
APA
Farrell, C., Buhidma, Y., Mumford, P., Heywood, W. E., Hällqvist, J., Flores-Aguilar, L., Andrews, E. J., Rahimzadah, N., Taso, O. S., Doran, E., Swarup, V., Head, E., Lashley, T., Mills, K., Toomey, C. E., & Wiseman, F. K. (2025). Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease. Acta Neuropathologica, 149(1). https://doi.org/10.1007/s00401-025-02889-0
Vancouver
Farrell C, Buhidma Y, Mumford P, Heywood WE, Hällqvist J, Flores-Aguilar L, et al. Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease. Acta Neuropathologica. 2025;149(1). doi:10.1007/s00401-025-02889-0
BibTeX
@article{Farrell2025,
author = {Farrell, Clíona and Buhidma, Yazead and Mumford, Paige and Heywood, Wendy E and Hällqvist, Jenny and Flores-Aguilar, Lisi and Andrews, Elizabeth J and Rahimzadah, Negin and Taso, Orjona Stella and Doran, Eric and Swarup, Vivek and Head, Elizabeth and Lashley, Tammaryn and Mills, Kevin and Toomey, Christina E and Wiseman, Frances K},
title = {Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease},
journal = {Acta Neuropathologica},
year = {2025},
volume = {149},
number = {1},
doi = {10.1007/s00401-025-02889-0}
}
EUVIMED